Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Irwin

Showing results (181-190 of 209) with videos related to

Pageof 21
Sort By:
Applied Neuropsychology. Child|February 17, 2024
RETRACTED ARTICLE: Psychological Resilience, Emotional Symptoms, and Recovery Duration in Adolescent Sport-Related ConcussionJulia C Nahman, Cody Staples, Lauren N Irwin Harper, et al.
Psychological Assessment|June 2, 2020
Rethinking hyperactivity in pediatric ADHD: Preliminary evidence for a reconceptualization of hyperactivity/impulsivity from the perspective of informant perceptual processesMichael J Kofler, Nicole B Groves, Leah J Singh, et al.
Journal of the American Pharmacists Association : Japha|April 6, 2021
Examining nonprescription syringe sales in Massachusetts and Rhode Island community pharmaciesTraci C Green, Thomas Stopka, Ziming Xuan, et al.
Child Neuropsychology : a Journal on Normal and Abnormal Development in Childhood and Adolescence|January 18, 2021
Activities of daily living and working memory in pediatric attention-deficit/hyperactivity disorder (ADHD)Lauren N Irwin, Elia F Soto, Elizabeth S M Chan, et al.
Journal of the American Pharmacists Association : Japha|October 20, 2023
Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chainsTraci C Green, Joseph Silcox, Derek Bolivar, et al.
Research in Social & Administrative Pharmacy : RSAP|February 23, 2024
"I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materialsAdriane N Irwin, Mary Gray, Daniel Ventricelli, et al.
Diabetes, Obesity & Metabolism|May 2, 2015
Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharideS Patterson, M de Kort, N Irwin, et al.
The Journal of Endocrinology|March 12, 2004
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activityB D Green, M H Mooney, V A Gault, et al.
The Journal of Endocrinology|October 27, 2006
Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob miceJ C Parker, K S Lavery, N Irwin, et al.
Metabolism: Clinical and Experimental|February 10, 2004
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.
Pageof 21

Showing results (181-190 of 209) with videos related to

Sort By:
Pageof 21
Applied Neuropsychology. Child|February 17, 2024
RETRACTED ARTICLE: Psychological Resilience, Emotional Symptoms, and Recovery Duration in Adolescent Sport-Related ConcussionJulia C Nahman, Cody Staples, Lauren N Irwin Harper, et al.
Psychological Assessment|June 2, 2020
Rethinking hyperactivity in pediatric ADHD: Preliminary evidence for a reconceptualization of hyperactivity/impulsivity from the perspective of informant perceptual processesMichael J Kofler, Nicole B Groves, Leah J Singh, et al.
Journal of the American Pharmacists Association : Japha|April 6, 2021
Examining nonprescription syringe sales in Massachusetts and Rhode Island community pharmaciesTraci C Green, Thomas Stopka, Ziming Xuan, et al.
Child Neuropsychology : a Journal on Normal and Abnormal Development in Childhood and Adolescence|January 18, 2021
Activities of daily living and working memory in pediatric attention-deficit/hyperactivity disorder (ADHD)Lauren N Irwin, Elia F Soto, Elizabeth S M Chan, et al.
Journal of the American Pharmacists Association : Japha|October 20, 2023
Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chainsTraci C Green, Joseph Silcox, Derek Bolivar, et al.
Research in Social & Administrative Pharmacy : RSAP|February 23, 2024
"I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materialsAdriane N Irwin, Mary Gray, Daniel Ventricelli, et al.
Diabetes, Obesity & Metabolism|May 2, 2015
Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharideS Patterson, M de Kort, N Irwin, et al.
The Journal of Endocrinology|March 12, 2004
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activityB D Green, M H Mooney, V A Gault, et al.
The Journal of Endocrinology|October 27, 2006
Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob miceJ C Parker, K S Lavery, N Irwin, et al.
Metabolism: Clinical and Experimental|February 10, 2004
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.
Pageof 21